Sign in
ACOG Stock Price, Chart, Stats & News
Alpha Cognition Inc. Common Stock
Save
107.32M
Market cap
–
Current P/E
26.88x
Forward P/E
ACOG chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 77.98% |
Operating margin | -220.88% |
Pretax margin | -202.24% |
Net margin | -202.24% |
Effective tax rate | – |
ROA | -25.92% |
ROE | -48.88% |
D/E | – |
Interest coverage ratio | -1647.67x |
ACOG valuation
P/E | – |
P/S | 7.38x |
P/B | 1.81x |
P/CF | -7.13x |
P/FCF | -4.72x |
P/OCF | -7.13x |
PEG | -0.37x |
EV multiple | -6.77x |
About
Alpha Cognition Inc. is a clinical-stage biopharmaceutical firm focused on creating therapies for neurological conditions such as Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Among its offerings is ZUNVEYL (benzgalantamine), intended for the management of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. The company is also progressing with other therapeutic programs, including ALPHA-0602, a gene therapy specifically for ALS, and ALPHA-0702 and ALPHA-0802, which are granulin epithelin motifs targeting various neurodegenerative disorders.
Similar securities
Based on sector and market capitalization
Report issue